Stay updated on Pediatric Safety of Dapagliflozin & Saxagliptin Clinical Trial

Sign up to get notified when there's something new on the Pediatric Safety of Dapagliflozin & Saxagliptin Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pediatric Safety of Dapagliflozin & Saxagliptin Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Added Revision: v3.4.3 and removed Revision: v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-05T19:50:50.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    Footer now shows Revision: v3.4.2, replacing the previous Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-12T03:50:13.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.0 to v3.4.1. No substantive changes to the study details or page layout were observed.
    Difference
    0.0%
    Check dated 2026-02-05T01:34:34.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    Added a glossary display option and standardized the QC labeling to 'Last Update Submitted that Met QC Criteria'. Capitalization for 'No FEAR Act Data' was applied and the page revision updated to v3.4.0.
    Difference
    0.1%
    Check dated 2026-01-28T21:41:32.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Page revision updated to v3.3.4. This appears to be a minor metadata update and does not modify the study content or user-facing functionality.
    Difference
    0.0%
    Check dated 2026-01-14T04:48:47.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    Locations section was updated: new site locations including California, Connecticut, Florida, Georgia, Idaho, New Jersey, Tennessee, Texas, Virginia, and Quebec were added and the revision updated to v3.3.3. The corresponding location subsections (California Locations, Connecticut Locations, Florida Locations, Georgia Locations, Idaho Locations, New Jersey Locations, Tennessee Locations, Texas Locations, Virginia Locations, Quebec Locations) were removed, and the HHS Vulnerability Disclosure entry was deleted.
    Difference
    0.5%
    Check dated 2025-12-23T21:08:20.000Z thumbnail image

Stay in the know with updates to Pediatric Safety of Dapagliflozin & Saxagliptin Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pediatric Safety of Dapagliflozin & Saxagliptin Clinical Trial page.